Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 May 30:2018:9596054.
doi: 10.1155/2018/9596054. eCollection 2018.

Plasminogen Activator Inhibitor-1 Level Correlates with Lipoprotein Subfractions in Obese Nondiabetic Subjects

Sándor Somodi  1   2 , Ildikó Seres  1 , Hajnalka Lőrincz  1 , Mariann Harangi  1 , Péter Fülöp  1 , György Paragh  1
Affiliations

Plasminogen Activator Inhibitor-1 Level Correlates with Lipoprotein Subfractions in Obese Nondiabetic Subjects

Sándor Somodi et al. Int J Endocrinol. .

Abstract

Background: The elevated level of plasminogen activator inhibitor-1 (PAI-1) in obese subjects with metabolic syndrome and in patients with type 2 diabetes is well established. The association of plasma PAI-1 and lipid metabolism is still unclear. The aim of the present study was to determine the relationship between plasma PAI-1 levels and the distribution of lipoprotein subfractions in obese and lean nondiabetic individuals.

Subjects and methods: We enrolled fifty nondiabetic obese patients and thirty-two healthy volunteers. Lipoprotein subfractions were detected with Lipoprint System. Plasma PAI-1, tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and myeloperoxidase (MPO) concentrations were determined with enzyme-linked immunosorbent assay (ELISA), while serum paraoxonase-1 (PON1) activities were measured by spectrophotometry.

Results: The TNF-α, IL-6, oxidized low-density lipoprotein (oxLDL), and MPO levels were found to be significantly higher, while PON1 paraoxonase and arylesterase activities were nonsignificantly lower in the obese patients. Strong significant negative correlations were found between plasma PAI-1 concentration and mean LDL size, as well as between PAI-1 concentrations and the levels of the large and intermediate high-density lipoprotein (HDL) subfractions. In multiple regression analysis, PAI-1 was predicted by waist circumference and intermediate HDL subfraction.

Conclusion: The significant correlations between PAI-1 levels and lipoprotein subfractions indicate the link between PAI-1 and lipid metabolism in obesity.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Plasma concentrations of plasminogen activator inhibitor-1 (PAI-1) in nondiabetic obese and lean participants (obese: 6.58 [5–8.58] and control: 2.93 [1.8–5.23] ng/ml; p < 0.001).
Figure 2
Figure 2
Correlations between plasminogen activator inhibitor-1 (PAI-1) and (a) high-density lipoprotein cholesterol (HDL-C), (b) apolipoprotein AI (apoAI), (c) large HDL subfraction, and (d) intermediate HDL subfraction in nondiabetic obese (●) and normal-weight controls (∆).
See this image and copyright information in PMC

References

    1. Calle E. E., Thun M. J., Petrelli J. M., Rodriguez C., Heath C. W., Jr. Body-mass index and mortality in a prospective cohort of U.S. adults. The New England Journal of Medicine. 1999;341(15):1097–1105. doi: 10.1056/NEJM199910073411501. - DOI - PubMed
    1. Van Gaal L. F., Mertens I. L., De Block C. E. Mechanisms linking obesity with cardiovascular disease. Nature. 2006;444(7121):875–880. doi: 10.1038/nature05487. - DOI - PubMed
    1. Ouchi N., Parker J. L., Lugus J. J., Walsh K. Adipokines in inflammation and metabolic disease. Nature Reviews Immunology. 2011;11(2):85–97. doi: 10.1038/nri2921. - DOI - PMC - PubMed
    1. Lijnen H. R. Pleiotropic functions of plasminogen activator inhibitor-1. Journal of Thrombosis and Haemostasis. 2005;3(1):35–45. doi: 10.1111/j.1538-7836.2004.00827.x. - DOI - PubMed
    1. Lijnen H. R., Collen D. 1 Mechanisms of physiological fibrinolysis. Baillière's Clinical Haematology. 1995;8(2):277–290. doi: 10.1016/S0950-3536(05)80268-9. - DOI - PubMed

LinkOut - more resources